Evidence map›Paper›PMID 18071002›Full record

Trial reportDiabetes care2008

Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program.

Richard R Rubin, Yong Ma, David G Marrero, Mark Peyrot, Elizabeth L Barrett-Connor, Steven E Kahn, Steven M Haffner, David W Price, William C Knowler, Diabetes Prevention Program Research Group

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 5 pooled it
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 5 syntheses or guidelines pooled it, 243 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. A psychoeducational intervention (SWEEP) for depressed women with diabetes.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2012
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Review
  20. Review

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

Richard R RubinDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. rrubin4@jhmi.edu
Yong Ma
David G Marrero
Mark Peyrot
Elizabeth L Barrett-Connor
Steven E Kahn
Steven M Haffner
David W Price
William C Knowler
Diabetes Prevention Program Research Group
George Washington University · USIndiana University – Purdue University Indianapolis · USJohns Hopkins Medicine · USJohns Hopkins University · USNational Institute of Diabetes and Digestive and Kidney Diseases · USThe University of Texas Health Science Center at San Antonio · USUniversity of California, San Diego · USUniversity of Colorado Denver · USUniversity of Washington · US

Funding

PRIMARY PREVENTION TRIAL--DATA COORDINATING CENTERU01DK048489 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI JABLONSKI, KATHLEEN ANN, TEMPROSA, MARINELLA · 1994 to 2021
$84.8M
Native Americans: Diabetes Mellitus/Chronic DiseasesZ01DK069000 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KNOWLER, WILLIAM C · 1986 to 2008
$680k
Intramural NIH HHSNIDDK NIH HHS U01 DK048489
6 · The paper itself

Abstract

objectiveTo assess the association between elevated depression symptoms or antidepressant medicine use on entry to the Diabetes Prevention Program (DPP) and during the study and the risk of developing diabetes during the study. RESEARCH DESIGN AND

methodsDPP participants (n = 3,187) in three treatment arms (intensive lifestyle [ILS], metformin [MET], and placebo [PLB]) completed the Beck Depression Inventory (BDI) and reported their use of antidepressant medication at randomization and throughout the study (average duration in study 3.2 years).

resultsWhen other factors associated with the risk of developing diabetes were controlled, elevated BDI scores at baseline or during the study were not associated with diabetes risk in any arm. Baseline antidepressant use was associated with diabetes risk in the PLB (hazard ratio 2.25 [95% CI 1.38-3.66]) and ILS (3.48 [1.93-6.28]) arms. Continuous antidepressant use during the study (compared with no use) was also associated with diabetes risk in the same arms (PLB 2.60 [1.37-4.94]; ILS 3.39 [1.61-7.13]), as was intermittent antidepressant use during the study in the ILS arm (2.07 [1.18-3.62]). Among MET arm participants, antidepressant use was not associated with developing diabetes.

conclusionsA strong and statistically significant association between antidepressant use and diabetes risk in the PLB and ILS arms was not accounted for by measured confounders or mediators. If future research finds that antidepressant use independently predicts diabetes risk, efforts to minimize the negative effects of antidepressant agents on glycemic control should be pursued.

Indexed as

AdultAntidepressive AgentsDepressionDiabetes MellitusFemaleHumansHypoglycemic AgentsLife StyleMaleMetforminMiddle AgedRisk FactorsAntidepressive AgentsHypoglycemic AgentsMetformin

Identifiers

PMID18071002
PMCPMC2373986
OpenAlexW2098858396

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.